Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Mar;115(3):572-83.
doi: 10.1172/JCI24283.

Unchain my heart: the scientific foundations of cardiac repair

Stefanie Dimmeler  1 , Andreas M Zeiher, Michael D Schneider
Affiliations
Review

Unchain my heart: the scientific foundations of cardiac repair

Stefanie Dimmeler et al. J Clin Invest. 2005 Mar.

Abstract

In humans, the biological limitations to cardiac regenerative growth create both a clinical imperative--to offset cell death in acute ischemic injury and chronic heart failure--and a clinical opportunity; that is, for using cells, genes, and proteins to rescue cardiac muscle cell number or in other ways promote more efficacious cardiac repair. Recent experimental studies and early-phase clinical trials lend credence to the visionary goal of enhancing cardiac repair as an achievable therapeutic target.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Sources of cells for cardiac repair, and routes of their administration. (A) Cells in current human trials include skeletal muscle myoblasts, unfractionated bone marrow, and circulating (endothelial) progenitor cells. Cells in preclinical studies include bone marrow MSCs, multipotent cells from other sources, and novel progenitor or stem cells discovered in the adult myocardium; see text for details. (B) Existing trials use intracoronary delivery routes (over-the-wire balloon catheters), intramuscular delivery via catheters (e.g., the NOGA system for electromechanical mapping), or direct injection during cardiac surgery. Not represented here are the theoretical potential for systemic delivery, suggested by the homing of some cell types to infarcted myocardium (39), and strategies to mobilize endogenous cells from other tissue sites to the heart.
Figure 2
Figure 2
Mechanisms of action. Progenitor cells may improve functional recovery of infarcted or failing myocardium by various potential mechanisms, including direct or indirect improvement of neovascularization. Paracrine factors released by progenitor cells may inhibit cardiac apoptosis, affect remodeling, or enhance endogenous repair (e.g., by tissue-resident progenitor cells). Differentiation into cardiomyocytes may contribute to cardiac regeneration. The extent to which these different mechanisms are active may critically depend on the cell type and setting, such as acute or chronic injury.
Figure 3
Figure 3
Mobilization and homing. After intravascular delivery or mobilization from bone marrow, progenitor cells are targeted to the sites of injury by multiple signals. Homing is mediated by a multistep process including the initial adhesion, transmigration, and invasion. Molecular mechanisms contributing to these individual steps are indicated but likely vary depending on the cell type and model. EPO, erythropoietin; MCP-1, monocyte chemoattractant protein–1.
Figure 4
Figure 4
Current challenges for cell-based therapy in cardiac repair include identifying the origins of the novel cardiac progenitor and stem cells found within the heart, pinpointing the biologically active cells from bone marrow and other mixed populations, optimizing cell mobilization and homing, augmenting grafted cells’ survival, defining the cues for cardiac differentiation, promoting donor cell proliferation ex vivo (or, if safe, in vivo), and exploiting cell therapy as a platform for secretory signals.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Poss KD, Wilson LG, Keating MT. Heart regeneration in zebrafish. Science. 2002;298:2188–2190. - PubMed
    1. Bettencourt-Dias M, Mittnacht S, Brockes JP. Heterogeneous proliferative potential in regenerative adult newt cardiomyocytes. J. Cell Sci. 2003;116:4001–4009. - PubMed
    1. Pasumarthi KB, Nakajima H, Nakajima HO, Soonpaa MH, Field LJ. Targeted expression of cyclin D2 results in cardiomyocyte DNA synthesis and infarct regression in transgenic mice. Circ. Res. 2005;96:110–118. - PubMed
    1. Oh H, et al. Telomere attrition and chk2 activation in human heart failure. Proc. Natl. Acad. Sci. U. S. A. 2003;100:5378–5383. - PMC - PubMed
    1. Foo RS-Y, Mani K, Kitsis RN. Death begets failure in the heart. J. Clin. Invest. 2005;115:565–571. doi:10.1172/JCI200524569. - PMC - PubMed

Publication types